Outcomes Among Homeless Patients With Non–Small-Cell Lung Cancer: A County Hospital Experience

por Concannon, Kyle F., Thayer, John H., Wu, Qian V., Jenkins, Isaac C., Baik, Christina S., Linden, Hannah M.
Publicado 2020

Effect of (18)F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer

por Wangerin, Kristen A., Muzi, Mark, Peterson, Lanell M., Linden, Hannah M., Novakova, Alena, O'Sullivan, Finbarr, Kurland, Brenda F., Mankoff, David A., Kinahan, Paul E.
Publicado 2015

Evaluation of Cross-Calibrated (68)Ge/(68)Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials

por Byrd, Darrin W., Doot, Robert K., Allberg, Keith C., MacDonald, Lawrence R., McDougald, Wendy A., Elston, Brian F., Linden, Hannah M., Kinahan, Paul E.
Publicado 2016

Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey

por Kurland, Brenda F., Aggarwal, Sameer, Yankeelov, Thomas E., Gerstner, Elizabeth R., Mountz, James M., Linden, Hannah M., Jones, Ella F., Bodeker, Kellie L., Buatti, John M.
Publicado 2016

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

por Kazerouni, Anum S., Peterson, Lanell M., Jenkins, Isaac, Novakova-Jiresova, Alena, Linden, Hannah M., Gralow, Julie R., Hockenbery, David M., Mankoff, David A., Porter, Peggy L., Partridge, Savannah C., Specht, Jennifer M.
Publicado 2023

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

por Kurland, Brenda F, Gadi, Vijayakrishna K, Specht, Jennifer M, Allison, Kimberly H, Livingston, Robert B, Rodler, Eve T, Peterson, Lanell M, Schubert, Erin K, Chai, Xiaoyu, Mankoff, David A, Linden, Hannah M
Publicado 2012

Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network

por Jones, Ella F., Buatti, John M., Shu, Hui-Kuo, Wahl, Richard L., Kurland, Brenda F., Linden, Hannah M., Mankoff, David A., Rubin, Daniel L., Tata, Darrell, Nordstrom, Robert J., Hadjiyski, Lubomir, Holdhoff, Matthias, Schwartz, Lawrence H.
Publicado 2020

(18)F-fluorodeoxyglucose (FDG) PET or (18)F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-...

por Romine, Perrin E., Peterson, Lanell M., Kurland, Brenda F., Byrd, Darrin W., Novakova-Jiresova, Alena, Muzi, Mark, Specht, Jennifer M., Doot, Robert K., Link, Jeanne M., Krohn, Kenneth A., Kinahan, Paul E., Mankoff, David A., Linden, Hannah M.
Publicado 2021

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

por Bardia, Aditya, Chandarlapaty, Sarat, Linden, Hannah M., Ulaner, Gary A., Gosselin, Alice, Cartot-Cotton, Sylvaine, Cohen, Patrick, Doroumian, Séverine, Paux, Gautier, Celanovic, Marina, Pelekanou, Vasiliki, Ming, Jeffrey E., Ternès, Nils, Bouaboula, Monsif, Lee, Joon Sang, Bauchet, Anne-Laure, Campone, Mario
Publicado 2022

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast canc...

por Bardia, Aditya, Mayer, Ingrid, Winer, Eric, Linden, Hannah M., Ma, Cynthia X., Parker, Barbara A., Bellet, Meritxell, Arteaga, Carlos L., Cheeti, Sravanthi, Gates, Mary, Chang, Ching-Wei, Fredrickson, Jill, Spoerke, Jill M., Moore, Heather M., Giltnane, Jennifer, Friedman, Lori S., Chow Maneval, Edna, Chan, Iris, Jhaveri, Komal
Publicado 2022